Provision was made for dose reduction if patients experienced drug-related toxicities. Missed doses of day 8 gemcitabine were not made up. Eleven patients total (all on Schedule 2/1) received growth factor support, including one patient before the amendment. The sunitinib dose was interrupted in 25 patients and reduced in 12 patients across all cohorts. The gemcitabine dose was not modified in any patients. The study design was modified on Schedule 2/1 to allow growth factor support during cycle 1. 